Nichi-Iko Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nichi-Iko Pharmaceutical Co., Ltd.
As Japan’s Syphilis Cases Surge, So Do Calls For More Therapeutics
As Japan faces skyrocketing syphilis cases, hopes have been high among domestic physicians for a single-dose therapeutic in the form of benzylpenicillin injection. But the country has approved the drug only recently and in answer to a push from doctors on the front line.
Down But Not Out: Nichi-Iko Hives Off Sagent, Exits North America
Seven years after it paid almost three quarters of a billion dollars for US-based Sagent, troubled Nichi-Iko is offloading the struggling business.
Who’s Hired? Nichi-Iko Looks To Sandoz For Fresh Leadership
Nichi-Iko has revealed its choice of new leadership, looking to Sandoz Japan for its next president and CEO. Meanwhile, Ethypharm and Krka have made fresh appointments in the UK and Centrient has named a new chief quality officer.
Nichi-Iko Secures Up To ¥98.5bn Debt Relief As ADR Pushes Ahead
Troubled Japanese firm Nichi-Iko has currently has ¥55.8bn of debt forgiveness, which may expand to ¥98.5bn in the future. It currently faces regular payments until 2033 to settle all of its debts.
- Generic Drugs
- OTC, Consumer
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Large Molecule
- Other Names / Subsidiaries
- Elmed Eisai Co., Ltd
- Nichi-Iko Medical Practice Institution Co., Ltd.
- Yakuhan Pharmaceutical Co., Ltd.
- Nichi-Iko Pharma Tech Co., Ltd.
- Omega Laboratories Limited
- Sagent Pharmaceuticals Inc.
- Nihon Iyakuhin Kogyo Co., Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.